Global Market Study on Pulmonary Fibrosis Treatment: Effective Disease Management Holds the Future


Pulmonary Fibrosis Treatment  Market
  • Published On : Aug-2019 |
  • Pages : 230 Pages |
  • Format :

A recent market study published by the company “Pulmonary Fibrosis Treatment Market: Global Industry Analysis 2014–2018 & Forecast, 2019–2029” consists of a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historic as well as current growth parameters of the pulmonary fibrosis treatment market, the growth prospects of the market can be obtained with maximum precision. The report features the unique and salient factors that are likely to significantly impact the development of the pulmonary fibrosis treatment market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in the pulmonary fibrosis treatment market in the upcoming years. The report provides detailed information about the current and future growth prospects of the pulmonary fibrosis treatment market in the most comprehensive manner for the better understanding of readers.

Chapter 01 – Executive Summary

The report commences with the executive summary of the pulmonary fibrosis treatment market, which includes the summary of key findings and key statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the pulmonary fibrosis treatment market.

Chapter 02 – Market Overview

Readers can find the detailed taxonomy and the definition of the pulmonary fibrosis treatment market in this chapter, which will help them understand the basic information about the pulmonary fibrosis treatment market dynamics and cost structure. A list of key distributors and suppliers, as well as a list of key market participants is included in the report.

Chapter 03 – Key Market Trends

The report provides the key market trends that are expected to impact the market growth significantly during the forecast period. Detailed industry trends are provided in this section, along with a new treatment approach and product innovations.

Chapter 04 – Key Success Factors

This section includes the key inclusions of the report. It includes the regulatory scenario, disease epidemiology, pipeline assessment, and reimbursement scenario for each region.

Chapter 05 – Global Market Demand/Consumption (Value or Size in US$ Mn) Analysis

This chapter includes a detailed analysis of the historical pulmonary fibrosis treatment market, along with opportunity analysis in the future. Readers can also find the absolute opportunity from 2019 to 2020, and the incremental opportunity for the forecast period.

Chapter 06 – Market Background

This chapter includes a detailed analysis of the macro-economic factors, forecast factors, and market dynamics such as the drivers and restraints of the market, and opportunity analysis.

Chapter 07 – Global Pulmonary Fibrosis Treatment Market Analysis 2014–2028 & Forecast 2019–2029, By Therapy Type

Based on the therapy type, the pulmonary fibrosis treatment market is segmented into monotherapy, combination therapy and symptomatic treatment. In this chapter, readers can find information about the key trends and developments in the pulmonary fibrosis treatment market and market attractiveness analysis based on the drug class.

Chapter 08 – Global Pulmonary Fibrosis Treatment Market Analysis 2014–2028 & Forecast, 2019–2029, By Indication

Based on the indication, the pulmonary fibrosis treatment market is segmented into idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis and others. In this chapter, readers can find information about the key trends and developments in the pulmonary fibrosis treatment market and market attractive analysis.

Chapter 09 – Global Pulmonary Fibrosis Treatment Market Analysis 2014–2028 & Forecast, 2019–2029, By Distribution Channel

Based on the distribution channel, the pulmonary fibrosis treatment market is segmented into hospital pharmacies, retail pharmacies and mail order pharmacies. In this chapter, readers can find information about the key trends and developments in the pulmonary fibrosis treatment market and market attractive analysis based on the distribution channel.

Chapter 10 – Global Pulmonary Fibrosis Treatment Market Analysis 2014–2028 & Forecast, 2019–2029, By Region

This chapter explains how the pulmonary fibrosis treatment market will grow across various geographic regions, such as North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa (MEA).

Chapter 11 – North America Pulmonary Fibrosis Treatment Market Analysis 2014–2018 & Forecast, 2019–2029

This chapter includes a detailed analysis of the growth of the North America pulmonary fibrosis treatment market, along with a country-wise assessment that includes the U.S. and Canada. Readers can also find the regional trends, regulations, and market growth based on the end users and countries in North America.

Chapter 12 – Latin America Pulmonary Fibrosis Treatment Market Analysis 2014–2018 & Forecast, 2019–2029

Readers can find detailed information about several factors, such as the pricing analysis and the regional trends, which are impacting the growth of the Latin America pulmonary fibrosis treatment market. This chapter also includes the growth prospects of the pulmonary fibrosis treatment market in the leading LATAM countries such as Brazil, Mexico, and the Rest of Latin America.

Chapter 13 – Europe Pulmonary Fibrosis Treatment Market Analysis 2014–2018 & Forecast, 2019–2029

Important growth prospects of the pulmonary fibrosis treatment market based on its end users in several countries, such as Germany, the UK, France, Spain, Italy, Russia, BENELUX, and Rest of Europe, are included in this chapter.

Chapter 14 – East Asia Pulmonary Fibrosis Treatment Market Analysis 2014–2018 & Forecast, 2019–2029

In this chapter, China, Japan, and South Korea are among the prominent countries in the region, which are the prime subjects of assessment to obtain the growth prospects of the East Asia pulmonary fibrosis treatment market. Readers can find detailed information about the growth parameters of the East Asia pulmonary fibrosis treatment market during the period 2019–2029.

Chapter 15 – South Asia Pulmonary Fibrosis Treatment Market Analysis 2014–2018 & Forecast, 2019–2029

Readers can find important factors that can significantly impact the growth of the pulmonary fibrosis treatment market in India, Thailand, Indonesia, Malaysia, and the rest of South Asia during the forecast period based on the market segmentation.

Chapter 16 – Oceania Pulmonary Fibrosis Treatment Market Analysis 2014–2018 & Forecast, 2019–2029

In this chapter, Australia and New Zealand are the leading countries in the Oceania region, which are the prime subjects of assessment to obtain the growth prospects of the Oceania pulmonary fibrosis treatment market.

Chapter 17 – MEA Pulmonary Fibrosis Treatment Market Analysis 2014–2018 & Forecast, 2019–2029

This chapter provides information about how the pulmonary fibrosis treatment market will grow in the major countries in the MEA region, such as North Africa, GCC Countries, South Africa, and the rest of MEA, during the period 2019–2029.

Chapter 18 – Market Structure Analysis

This chapter enables readers to understand the market structure based on the revenue generation of key market players.

Chapter 19 – Competition Landscape, Company Share and Company Profiles

In this chapter, readers can find a comprehensive list of all the leading stakeholders in the pulmonary fibrosis treatment market, along with detailed information about each company, which includes the company overview, revenue shares, strategic overview, and recent company developments. Some of the market players featured in the report are Genentech, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Dr. Reddy's Laboratories Ltd., Alkem Laboratories Ltd., Alniche Life Sciences Pvt Ltd, MHS Pharmaceuticals, Torrent Pharmaceuticals Ltd, Anthem Biopharma Pvt Ltd., Panacea Biotec, Zydus Healthcare Ltd., Fresenius Kabi India Pvt Ltd., Sun Pharmaceutical Industries Ltd and others.

Chapter 20 – Assumptions and Acronyms

This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the report.

Chapter 21 – Research Methodology

This chapter helps readers understand the research methodology followed to obtain the various conclusions as well as important qualitative and quantitative information about the pulmonary fibrosis treatment market.

Pulmonary Fibrosis Treatment Market Controlled by Two Key Manufacturers

The pulmonary fibrosis treatment market is dominated by two key global manufacturers. Pharmaceutical & biopharmaceutical companies Genentech Inc. and Boehringer Ingelheim International GmbH control the global pulmonary fibrosis treatment market by generating over 90% of the revenue. Manufacturers of pulmonary fibrosis treatment drugs are mainly competing on the basis of geographical product footprint, collaborations for developing new drugs as well as to increase the geographical reach, superior efficacy of the product, etc. These two manufacturers are mostly engaging in pipeline development, drug launches, collaborations and partnerships to enhance their revenue generation across the world. For example, in July 2019, Boehringer Ingelheim entered into collaboration and license agreement with Bridge Biotherapeutics to strengthen its Idiopathic Pulmonary Fibrosis (IPF) Pipeline.

pulmonary fibrosis treatment market

Drug Approvals and Launches

Apart from traditional off-label corticosteroid treatment options, drugs such as Ofev (nintedanib) by Boehringer Ingelheim Pharmaceuticals, Inc. and Esbriet (Pirfenidone) by Genentech Inc. received marketing approval in 2014 changing the dynamics of the pulmonary fibrosis treatment market. Similarly, various companies are applying for FDA approval or orphan drug designation for their respective products such as, In August 2019, EmphyCorp Inc. applied for NDA marketing application for its non-steroidal nasal spray for the treatment of Interstitial Lung Diseases (ILD), which includes pulmonary fibrosis and cystic fibrosis.

Breakthrough Therapies for Effective Treatment of Pulmonary Fibrosis

The cause of the pulmonary fibrosis is unknown making the treatment options limited. The development of novel therapies for the pulmonary fibrosis treatment are majorly halt by the lack of understanding of the prognosis of the disease. Various organizations, universities, pharmaceutical and biopharmaceutical companies are awarding grants, fellowships for the possible invention of the causative factor as well as breakthrough therapy. For example, in 2017, National Heart, Lung, and Blood Institute of the National Institutes of Health grant awarded over US$ 2.1 million to Weill Cornell Medicine researchers for the span of over 4 years to find out the mechanism causing scar tissues in lungs.

Ageing Population Increasing Opportunities for the Market

The chances of developing pulmonary fibrosis increases significantly with the increasing age. As per the Pulmonary Fibrosis Foundation, more than 80% of cases of pulmonary fibrosis are in people aged above 40 years. The patient who are at risk of developing pulmonary fibrosis can develop the disease with slight exposure to trigger factors. Age plays a major role in initiating or preventing the onset of disease. Increasing availability of novel therapies for the treatment of various diseases resulting in increased life expectancy and decreasing fertility rate across the world is expected to impact the higher population aged above 60 years as compared to children below 10 years by the end of 2030 (United Nations Estimate). Currently, more than 66% of people aged over 60 years are living in the developing region and the number is growing rapidly as compared to the developed region.

Pulmonary fibrosis treatment Market: Competitive Landscape

This part of the report consists of the profiles of key players in the pulmonary fibrosis treatment market based on their market shares, product offerings, differential strategies, marketing approach, and company dashboard. Some of the important players featured in the pulmonary fibrosis treatment market report include Genentech, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Dr. Reddy's Laboratories Ltd., and others.

Pulmonary fibrosis treatment: Definition

Pulmonary fibrosis is interstitial lung disease in which the scarring of the lung tissue starts reducing the oxygen exchange area of the lungs. It is non-reversible disease and cannot be cured. Pulmonary fibrosis treatment drugs can help with the management of the disease for span of around 2 to 5 years.

Pulmonary fibrosis treatment Market: About the Report

The company conducted a research study on the pulmonary fibrosis treatment market for the forecast period 2019-2029. The report offers a comprehensive evaluation of the business opportunities available in the pulmonary fibrosis treatment market, with insights on the current trends, reimbursements, as well as regulatory scenario in the pulmonary fibrosis treatment market.

Pulmonary fibrosis treatment Market: Segmentation

The report offers a comprehensive taxonomy of the market based on the therapy type, indication, distribution channel, and region. By therapy type, the pulmonary fibrosis treatment market is segmented into monotherapy, combination therapy and symptomatic treatment. By indication, the pulmonary fibrosis treatment market is segmented as idiopathic pulmonary fibrosis, familial pulmonary fibrosis and others. By distribution channel, the pulmonary fibrosis treatment market is segmented into hospital pharmacies, retail pharmacies and mail order pharmacies. The pulmonary fibrosis treatment market has been analyzed across the regions of North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa (MEA).

Additional Questions Answered

Some of the additional questions addressed in this report on the pulmonary fibrosis treatment market:

  • What is the overall revenue generation potential of the pulmonary fibrosis treatment market across all regions?
  • Who are the key regional and global competitors? What are their portfolios in the pulmonary fibrosis treatment market?
  • What are the major challenges influencing the growth of the pulmonary fibrosis treatment market?
  • What are the breakthrough therapies arriving in the market during the forecast period?

Research Methodology

The market has been estimated based on a supply-demand approach. The market was first calculated based on the prevalence, diagnosis rate and treatment cost using pulmonary fibrosis treatment drugs in different regions/countries. Some of the other qualitative factors analyzed include the awareness level and the availability of pulmonary fibrosis treatment. This information is further validated with rigorous primary research (which includes interviews, surveys, in-person interactions, and the viewpoints of seasoned analysts) and secondary research (which includes verified paid sources, authentic trade journals, and resourceful databases). The research study on the pulmonary fibrosis treatment market also includes the top trends and the macro- as well as micro-economic factors shaping the pulmonary fibrosis treatment market. With this approach, the report on the pulmonary fibrosis treatment market estimates the industry attractiveness of every major segment in the market over the forecast period.

Company Profiles:

  • Genentech, Inc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Alkem Laboratories Ltd.
  • Alniche Life Sciences Pvt Ltd
  • MHS Pharmaceuticals
  • Torrent Pharmaceuticals Ltd
  • Anthem Biopharma Pvt Ltd
  • Panacea Biotec
  • Zydus Healthcare Ltd
  • Nuper Therapeutics
  • Fresenius Kabi India Pvt Ltd.
  • Sun Pharmaceutical Industries Ltd
Back To Top